Infliximab neutralizes the biological activity of TNF-α by binding with high affinity to the soluble (free floating in the blood) and transmembrane (located on the outer membranes of T cells and similar immune cells) forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors.
CAS：170277-31-3
分子式：C6428H9912N1694O1987S46
分子量：144188.23
纯度：98%
存储：Store at -20°C

Background:

Infliximab neutralizes the biological activity of TNF-α by binding with high affinity to the soluble (free floating in the blood) and transmembrane (located on the outer membranes of T cells and similar immune cells) forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors. Infliximab has high specificity for TNF-α, and does not neutralize TNF beta. Infliximab prevents disease in transgenic mice (a special type of mice biologically engineered to produce a human form of TNF-α and which are used to test the results of these drugs that might be expected in humans).

参考文献:
[1].Promising biological therapies for ulcerative colitis: A review of the literature.
Akiho H, et al. World J Gastrointest Pathophysiol. 2015 Nov 15;6(4):219-27. PMID: 26600980.
[2].Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
Keane J, et al. N Engl J Med. 2001 Oct 11;345(15):1098-104. PMID: 11596589.